Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
Type:
Grant
Filed:
May 4, 2020
Date of Patent:
June 14, 2022
Assignee:
LIPELLA PHARMACEUTICALS INC.
Inventors:
Jonathan H. Kaufman, Michael B. Chancellor
Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
Type:
Grant
Filed:
October 22, 2014
Date of Patent:
May 5, 2020
Assignee:
Lipella Pharmaceuticals, Inc.
Inventors:
Jonathan H. Kaufman, Michael B. Chancellor
Abstract: Methods and compositions for treating underactive bladder and/or symptoms thereof are disclosed, wherein the composition including an effective amount of a therapeutic agent and a pharmaceutically acceptable lipid vehicle is locally administered to the bladder, thereby treating the underactive bladder and/or symptoms thereof.
Type:
Application
Filed:
March 25, 2014
Publication date:
January 29, 2015
Applicant:
LIPELLA PHARMACEUTICALS, INC.
Inventors:
Jonathan KAUFMAN, Michael B. CHANCELLOR